---
title: "Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300357.SZ.md"
symbol: "300357.SZ"
name: "Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T06:06:23.663Z"
locales:
  - [en](https://longbridge.com/en/quote/300357.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300357.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300357.SZ.md)
---

# Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ)

## Company Overview

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of diagnostic and therapeutic products for allergic diseases in China and internationally. The company offers Changdi, a skin prick test product and dust mite drops; Changhao, an Artemisia annua pollen allergen sublingual drop; and Changdian, a dust mite skin prick test diagnostic kit. It is also involved in the research and development of cells and natural medicines.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.wolwobiotech.com](https://www.wolwobiotech.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: B (0.28)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 23 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.91% |  |
| Net Profit YoY | 35.20% |  |
| P/B Ratio | 4.53 |  |
| Dividend Ratio | 0.93% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 12425767498.41 |  |
| Revenue | 1088706691.27 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 16.48% | A |
| Profit Margin | 39.18% | A |
| Gross Margin | 95.25% | A |
| Revenue YoY | 15.91% | B |
| Net Profit YoY | 35.20% | B |
| Total Assets YoY | 9.75% | B |
| Net Assets YoY | 11.73% | B |
| Cash Flow Margin | 92.14% | C |
| OCF YoY | 15.91% | B |
| Turnover | 0.39 | C |
| Gearing Ratio | 3.71% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "15.91%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "35.20%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.53",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.93%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "12425767498.41",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1088706691.27",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "16.48%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "39.18%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "95.25%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "15.91%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "35.20%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "9.75%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "11.73%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "92.14%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "15.91%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.39",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "3.71%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 29.13 | 71/215 | 43.95 | 39.20 | 34.05 |
| PB | 4.53 | 179/215 | 6.20 | 5.53 | 4.79 |
| PS (TTM) | 11.41 | 189/215 | 15.59 | 14.16 | 12.12 |
| Dividend Yield | 0.93% | 103/215 | 0.90% | 0.80% | 0.71% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T16:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 50% |
| Overweight | 2 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 23.74 |
| Highest Target | 38.26 |
| Lowest Target | 38.26 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300357.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300357.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300357.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300357.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**